FDA Grants Accelerated Approval to Lynozyfic for Relapsed or Refractory Multiple Myeloma

The FDA granted accelerated approval to Lynozyfic, a BCMA-directed CD3 T-cell engager for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.